India, Aug. 18 -- The first FDA-cleared blood test that aids in the diagnosis of Alzheimer's disease has been launched by Labcorp (LH), a global life sciences and healthcare company.
The test, named Lumipulse pTau-217/Beta Amyloid 42 Ratio, is intended for adults aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. It is not intended for screening or use as a stand-alone diagnostic tool, and results must be interpreted along with other relevant medical data of the patient. Once ordered, patients can complete the blood draw in a healthcare provider's office or any of Labcorp's Patient Service Centers (PSCs) nationwide, the company noted.
Developed by Fujirebio Diagnostics Inc., the ...